Brief: Nyxoah Says FDA Regulatory Submission For Company's Genio® Device Is Complete, U.S. Approval On Track For End Of 2024
Sept 2 (Reuters) - Nyxoah SA NYXH.BR :
* NYXOAH SA - FDA REGULATORY SUBMISSION FOR COMPANY'S GENIO®
DEVICE IS COMPLETE, U.S. APPROVAL ON TRACK FOR END OF 2024
* NYXOAH SA - U.S. COMMERCIAL LAUNCH EXPECTED AT BEGINNING
OF
2025, FULLY FUNDED WITH OVER EUR 85 MILLION IN NEW CAPITAL
RAISED
Source text for Eikon: ID:nGNEQZMlL
Further company coverage: NYXH.BR
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nyxoah SA
See all newsBelgium's Nyxoah Q3 revenue rises on US commercialization
Brief: Nyxoah SA Q3 Gross Profit EUR 5.785 Million
Brief: Nyxoah SA Submits Pma Supplement To FDA To Expand Genio Indication To Complete Concentric Collapse Patients
Brief: Nyxoah Says Co Appoints Liam Kelly As Chief Executive Officer Effective October 1
Brief: Cvrx Appoints John Landry As Chief Financial Officer